Who is sponsoring NCT01293539?

NCT01293539 is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

What condition does NCT01293539 study?

NCT01293539 studies Retinoblastoma.

What drugs are being tested in NCT01293539?

Interventions: Melphalan hydrochloride.

What is the status of NCT01293539?

NCT01293539 is currently TERMINATED.

Last reviewed 2018-11-01 · How we verify

Intra-arterial Chemotherapy for the Treatment of Intraocular Retinoblastoma

NCT01293539 Phase 2 TERMINATED Results posted

The purpose of this study is to show that chemotherapy delivered directly through the artery supplying the eye (ophthalmic artery) to patients with retinoblastoma is a safe and effective treatment alternative to conventional systemic chemotherapy, external beam radiation, and surgical removal of the eye.

Details

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase	Phase 2
Status	TERMINATED
Enrolment	10
Start date	2011-03
Completion	2016-08

Conditions

Retinoblastoma

Interventions

Melphalan hydrochloride

Primary outcomes

Number of Patients Who Complete Therapy Without the Need for Additional Treatment Including Systemic Chemotherapy, External Beam Radiation, or Enucleation. — Within the first six months after the initial treatment.
The primary objective of this study is to show that intra-arterial delivery of the chemotherapeutic agent is successful in treating intraocular retinoblastoma, defined as avoiding systemic chemotherapy, external beam radiation, and enucleation.

Countries

United States